Novartis-Avidity Biosciences deal gets early clearance in US
Novartis and Avidity Biosciences have received antitrust clearance for their $12 billion deal from the US competition authorities. On Dec. 17, the agencies granted early termination of the waiting period under...To view the full article, register now.
Already a subscriber? Click here to view full article